// App-Quantinova.ai

3286 : “Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose”

Researchers

Presenter

  • Roberta Azevedo

Principal Investigators

  • Vinicius Campos Molla

  • Jessica Fernandes Ramos

  • Danilo Belchior Ponciano

  • Pedro Henrique Arruda De Moraes

  • Ana Rita Da Fonseca

  • Maria Cristina Nunez Seiwald

  • Mariana Serpa

  • Aliana Meneses Ferreira

  • Roberta Shcolnik Szor

  • Rayana Bomfim Leonel

  • Erick Menezes Xavier

  • Luciana Tucunduva

  • Vanderson Rocha

  • Yana Novis

  • Esper Kallas

  • Marcio Nucci

  • Celso Arrais-Rodrigues

Medical Centers

  • Hospital Sirio Libanes, Sao Paulo, Brazil

  • Universidade Federal de Sao Paulo, Sao Paulo, Brazil

  • Universidade de Sao Paulo (USP), Sao Paulo, Brazil

  • Department of Hematology and Hemotherapy, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil

  • Universidade Federal de São Paulo - UNIFESP/EPM, Sao Paulo, Brazil,

Locations

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Cytomegalovirus infection

Biomarkers

  • N/A

Drug/Treatment

  • Ganciclovir

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved